Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case-control study in Chinese children
- PMID: 35532821
- DOI: 10.1007/s00277-022-04836-5
Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case-control study in Chinese children
Erratum in
-
Correction to: Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case-control study in Chinese children.Ann Hematol. 2022 Jul;101(7):1457. doi: 10.1007/s00277-022-04869-w. Ann Hematol. 2022. PMID: 35608679 No abstract available.
Abstract
Immune thrombocytopenia (ITP) patients are at risk developing to systemic lupus erythematosus (SLE) in the future. Our study attempted to explore the potential risk factors for the development from ITP to SLE in Chinese children by statistical analysis. This study was a retrospective case-control study. Patients diagnosed with ITP and developed to SLE after the diagnosis of ITP were defined as the case group. The control group consisted of children with ITP but without developing to SLE was recruited with a ratio of 1:2. Besides univariable analysis, multivariable logistic regression was built to evaluate the potential risk factors. A total of 150 children was included with 50 in the case group and 100 in the control group. Median developing time from ITP to SLE was 34.5 [IQR 12.5, 58.75] months. ANA was found significantly different between the two groups in our study in the univariable analysis but not in the multivariable analysis (OR = 4.50, 95% CI 0.97 to 21.01). Age diagnosed ITP was positively associated with SLE (OR = 1.07 every 5 years, 95% CI 1.01 to 1.15) with alert point at 8 years old (sensitivity 0.82, specificity 0.60). A lower level of complement was also positively associated with SLE (OR = 8.33, 95% CI 1.62 to 42.91). A minimum 3-year of close follow-up for pediatric ITP patients was recommended to monitor the risk for developing SLE. Older age and hypocomplementemia were potential risk factors for the development from ITP to SLE.
Keywords: Antinuclear antibody; Children; Complement; Immune thrombocytopenia; Systemic lupus erythematosus.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Incidence and risk factors of systemic lupus erythematosus in patients with primary immune thrombocytopenia: a systematic review and meta-analysis.PeerJ. 2024 Apr 22;12:e17152. doi: 10.7717/peerj.17152. eCollection 2024. PeerJ. 2024. PMID: 38666084 Free PMC article.
-
Prognostic factors for the development of systemic lupus erythematosus in patients with immune thrombocytopenia.Arthritis Res Ther. 2022 Sep 6;24(1):213. doi: 10.1186/s13075-022-02901-y. Arthritis Res Ther. 2022. PMID: 36068638 Free PMC article.
-
Development of systemic lupus erythematosus in patients with immune thrombocytopenic purpura: A systematic meta-analysis.Autoimmun Rev. 2023 Apr;22(4):103297. doi: 10.1016/j.autrev.2023.103297. Epub 2023 Feb 11. Autoimmun Rev. 2023. PMID: 36781038 Free PMC article.
-
Childhood-onset systemic lupus erythematosus and immune thrombocytopenia: Prevalence and risk factors.Pediatr Blood Cancer. 2021 Aug;68(8):e29146. doi: 10.1002/pbc.29146. Epub 2021 May 27. Pediatr Blood Cancer. 2021. PMID: 34047041
-
Immune thrombocytopenia in systemic lupus erythematosus: Prevalence, risk factors, and a novel predictive model for risk assessment.Med Clin (Barc). 2024 May 31;162(10):461-469. doi: 10.1016/j.medcli.2023.12.012. Epub 2024 Feb 20. Med Clin (Barc). 2024. PMID: 38383267 English, Spanish.
Cited by
-
Incidence and risk factors of systemic lupus erythematosus in patients with primary immune thrombocytopenia: a systematic review and meta-analysis.PeerJ. 2024 Apr 22;12:e17152. doi: 10.7717/peerj.17152. eCollection 2024. PeerJ. 2024. PMID: 38666084 Free PMC article.
-
Isolated thrombocytopenia as the initial manifestation of childhood-onset systemic lupus erythematosus: A case report.Medicine (Baltimore). 2025 Jun 13;104(24):e42874. doi: 10.1097/MD.0000000000042874. Medicine (Baltimore). 2025. PMID: 40527843 Free PMC article.
-
Predictors for spontaneous remission in childhood chronic immune thrombocytopenia.Ann Hematol. 2024 Dec;103(12):5181-5189. doi: 10.1007/s00277-024-06056-5. Epub 2024 Oct 27. Ann Hematol. 2024. PMID: 39463182
References
-
- Swinkels M, Rijkers M, Voorberg J, Vidarsson G, Leebeek FWG, Jansen AJG (2018) Emerging concepts in immune thrombocytopenia. Front Immunol 30(9):880. https://doi.org/10.3389/fimmu.2018.00880 - DOI
-
- Cines DB, Cuker A, Semple JW (2014) Pathogenesis of immune thrombocytopenia. Presse Med 43(4 Pt 2):e49-59. https://doi.org/10.1016/j.lpm.2014.01.010 - DOI - PubMed
-
- Yong M, Schoonen WM, Li L, el al, (2010) Epidemiology of paediatric immune thromhocvtopenia in the general practice research database. Br J Haematol 149:855–864. https://doi.org/10.1111/j.1365-2141.2010.08176.x - DOI - PubMed
-
- Yehudai D, Toubi E, Shoenfeld Y, Vadasz Z (2013) Autoimmunity and novel therapies in immune-mediated thrombocytopenia. Semin Hematol 50(Suppl 1):S100–S108. https://doi.org/10.1053/j.seminhematol.2013.03.015 - DOI - PubMed
-
- Abbasi SY, Milhem M, Zaru L (2008) A positive antinuclear antibody test predicts for a poor response to initial steroid therapy in adults with idiopathic thrombocytopenic purpura. Ann Hematol 87(6):459–462. https://doi.org/10.1007/s00277-008-0448-1 - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical